## SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported: October 21, 2010)

# PDI, INC.

(Exact name of Registrant as specified in its charter)

DELAWARE (State or other jurisdiction of incorporation)

0-24249 (Commission File Number) 22-2919486 (IRS Employer Identification No.)

Morris Corporate Center 1, Building A 300 Interpace Parkway, Parsippany, NJ 07054 (Address of principal executive offices and zip Code)

(862) 207-7800 Registrant's telephone number, including area code:

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (1/ CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Item 8.01 Other Events.

On October 21, 2010, PDI, Inc. issued a press release announcing that it has signed an agreement with a top-5 pharmaceutical company which is expected to generate approximately \$15 million in revenues over its 12-month term.

A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

Statements contained in this Current Report on Form 8-K that are not statements of historical fact, including statements about expectations, beliefs and future events and financial performance, are forward-looking statements. These forward looking statements reflect, among other things, the Company's current expectations, plans, strategies and anticipated financial results and are based upon numerous assumptions involving judgments with respect to future economic, competitive, and market conditions and future business decisions, all of which are subject to known and unknown risks, uncertainties and other factors that may cause the Company's actual results to differ materially from those expressed or implied by these forward looking statements. Many of these risks are beyond the Company's ability to control or predict. For a discussion of some of the important risks and other factors that could cause actual results to differ materially from those indicated by the forward-looking statements, we encourage you to read the risk factors detailed from time to time in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2009 and the Company's subsequently filed Quarterly Reports on Form 10-Q. Furthermore, forward looking statements speak only as of the date they are made. The Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

#### Item 9.01 Financial Statements and Exhibits.

(c) Exhibits

99.1 Press Release dated October 21, 2010.

\* \* \* \* \* \* \*

**SIGNATURE** 

Pursuant to the requirements of the Securities Exchange Act of 1934,

the

registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PDI, INC.

By: /s/ Jeffrey Smith

Jeffrey Smith
Chief Financial Officer

Date: October 25, 2010



#### **PDI CONTACT:**

Amy Lombardi PDI, Inc. (862) 207-7866 <u>ALombardi@pdi-inc.com</u> www.pdi-inc.com

#### **INVESTOR CONTACT:**

Melody Carey Rx Communications Group, LLC (917) 322-2571 MCarey@RxIR.com

# PDI Announces New Business Win with Top 5 Pharma Company With Revenue Value of Approximately \$15 Million

**Parsippany, N.J., Oct. 21, 2010** – PDI, Inc. (Nasdaq: PDII), a leading provider of integrated promotional outsource services to health care companies, today announced a significant new contract sales engagement with an existing Top 5 global pharmaceutical client. The contract involves several products in the women's health therapeutic category and is scheduled to begin in early November 2010 and run for 12 months. This program is expected to generate revenue to PDI of approximately \$15 million over the life of the contract.

Under the program, PDI will provide the client with a dedicated sales team that will call on both women's health specialists and primary care physicians.

"This business expansion with a major client again demonstrates the value and high return on investment that PDI has been able to deliver to our customers," said Nancy Lurker, Chief

Executive Officer of PDI, Inc. "We are now looking forward to applying our deep expertise in the women's health category and providing high-impact service to our client. By securing new business wins with existing clients, such as today's announcement, as well as by gaining new clients and extending our current programs and services, we are confident of realizing the growth strategy we have set out for 2010 and beyond."

### About PDI, Inc.

PDI is a leading provider of integrated promotional outsource services to established and emerging healthcare companies. The company is dedicated to maximizing the return on investment for its clients by providing strategic flexibility, sales and marketing expertise. For more information, please visit the company's website at www.pdi-inc.com.

#### **Forward-Looking Statements**

This press release contains forward-looking statements regarding future events and financial performance. These statements are based on current expectations and assumptions involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond PDI's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause PDI's actual results to be materially different from those expressed or implied by any forward-looking statement. For example, with respect to statements regarding projections of future revenues, actual results may differ materially from those set forth in this release based on the loss, early termination or significant reduction of any of our existing service contracts or the failure to meet performance goals in PDI's incentive-based arrangements with clients. Additionally, all forward-looking statements are subject to the risk factors detailed from time to time in PDI's periodic filings with the Securities and Exchange Commission, including without limitation, PDI's Annual Report on Form 10-K for the year ended December 31, 2009, and PDI's subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, PDI undertakes no obligation to revise or update publicly any forward-looking statements for any reason.